G-Sofosbuvir 400 mg (Tablet)
Unit Price: ৳ 50.00 (1 x 6: ৳ 300.00)
Strip Price: ৳ 300.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sofosbuvir |
| Company | Gonoshasthaya pharma ltd |
Title
G-G-Sofosbuvir
Categories
- Antiviral
- Hepatitis C Treatment
- Pharmaceutical
Description
G-G-Sofosbuvir is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
Indications
- Treatment of chronic hepatitis C (CHC) infection
- Efficacy in subjects with HCV genotype 1, 2, 3 or 4 infection
Pharmacology
- Nucleotide analog inhibitor of HCV NS5B RNA-dependent RNA polymerase
- Incorporates into HCV RNA and acts as a chain terminator
DosageAdministration
- TabletDosage: One 400 mg tablet taken once daily with or without food
- CombinationTherapy:
- Genotype1or4: Sofosbuvir + Peginterferon alfa + Ribavirin for 12 weeks
- Genotype2: Sofosbuvir + Ribavirin for 12 weeks
- Genotype3: Sofosbuvir + Ribavirin for 24 weeks
- RibavirinComboDuration: Up to 48 weeks for CHC patients with genotype 1 infection awaiting liver transplantation
- RenalImpairment: No dose recommendation for severe renal impairment or end stage renal disease
Interactions
- Reduced therapeutic effect with P-gp inducers
- Potential for serious symptomatic bradycardia with amiodarone co-administration
Contraindications
- Contraindicated in pregnant women or in men whose female partners are pregnant due to risks for birth defects and fetal death associated with Ribavirin
SideEffects
- Fatigue
- Headache
- Nausea
- Insomnia
- Anemia
- Pruritus
- Asthenia
- Rash
- Decreased appetite
- Chills
- Influenza-like illness
- Pyrexia
- Diarrhea
- Neutropenia
- Myalgia
- Irritability
PregnancyLactation
- Pregnancy Category B - no adequate and well-controlled studies
- Unknown presence of Sofosbuvir and its metabolites in human breast milk
PrecautionsWarnings
- Risk of serious symptomatic bradycardia with amiodarone co-administration
- Cardiac monitoring recommended in patients without alternative treatment options
- No established safety and effectiveness in children under 18 years of age
SpecialPopulations
- PediatricUse: Safety and effectiveness not established in children under 18
- GeriatricUse: Response rates for subjects over 65 similar to younger subjects; no dose adjustment warranted in geriatric patients
OverdoseEffects
- HighestDose: Single dose of G-G-Sofosbuvir 1200 mg
- Treatment: General supportive measures including vital sign monitoring and observation of clinical status
TherapeuticClass
Hepatic viral infections (Hepatitis C)
StorageConditions
Keep in a cool & dry place, protect from light